Last updated: August 18, 2026

Examiner: ELENISTE, PIERRE PAUL

Tech Center 1600 • Art Units: 1622

This examiner grants 36% of resolved cases

Performance Statistics

36.5%

Allow Rate

-23.5% vs TC avg

131

Total Applications

+32.1%

Interview Lift

1296

Avg Prosecution Days

Based on 85 resolved cases, 2023–2026

1.7%

§101 Eligibility

16.6%

§102 Novelty

47.4%

§103 Obviousness

24.5%

§112 Clarity

App #	Title	Status	Assignee
17262989	DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS	Non-Final OA	Ohio State Innovation Foundation
18556701	A hydroxycarboxylic acid for the treatment of cancer	Non-Final OA	UNIVERSITÄT ZÜRICH
14443862	SENSORILY ATTRACTIVE HYDRODISPERSION COMPRISING WAXES	Final Rejection	BEIERSDORF AG
18564008	FRAGRANCE COMPOSITION	Non-Final OA	Kao Corporation
17962610	PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES	Final Rejection	Medimmune Limited

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.